According to a recent report by Frost and Sullivan, the CRO industry continues, despite the resulting speculation uncertain economic climate, we extend recently. Avoid in this climate, biotechnology and pharmaceutical companies to invest in the in-house capacity for conducting the studies, and in turn more likely to trust in the direction of outsourcing to CROs vary. A warning was also reported, where â?? American market CRO Key Therapeutic Areasâ? expected to fight biotech and pharmaceutical organizations are likely not to pay into the current ongoing projects.

However, this trend is not expected to last over the long term. Barath Shankar Subramanian, senior industry analyst at Frost & Sullivan, pointed out that the annual CRO revenue growth is fourteen to fifteen percent of the region last year by ten percent this year. However, he says that the good news is that it is probable that will increase the annual revenues for the industry from now until 2015, two, rose from $ 10. Currently, 91 billion to $ 22. 87 billion. He says it is probably provided the sponsoring organizations to conduct strategic alliances with smaller service organizations or CROs. â?? After 10 years of talking about such relationships, CROs and pharmaceutical companies begin to forge them, â?? Subramanian says. Subramanian uses to illustrate the great Eli Lilly / Covance deal in August last year that demand, which Covance has contracted by $ 1, too. 6 billion worth of projects for the development of drugs Lilly for the next 10 years. Subramanian says: â??

That is the flavor of the season, we see some new models tested, though it was previously a purely commercial, with CROs to take a “wait and see approach to observe and strategic partnerships. â?? Another development is CROs enables sponsors to hold more promising molecules in the research cycle hold. Biotechnology and pharmaceutical companies were only starting often from products licensed under Phases I and II, which is in a great degree of uncertainty about the future of the assignment. These days, on the other hand, several of these companies can keep the products in its pipeline for more, which means they get closer to the market. This is made possible by the cost savings associated with CRO partnerships. This is a great step forward for sponsors and CROs.

Share and Enjoy:
  • Digg
  • del.icio.us
  • Facebook
  • NewsVine
  • Reddit
  • StumbleUpon
  • Google Bookmarks
  • Yahoo! Buzz
  • Twitter
  • Technorati
  • Live
  • LinkedIn
  • MySpace
  • StumbleUpon
  • Technorati
  • Tipd

Introduction The Indian pharmaceutical industry is now leading India, AOS science-based industries with wide ranging capabilities in the complex field of drug manufacture and technology. The Indian pharmaceutical industry has consistently risen to 9th 5 percent CAGR over the last five years and is currently estimated to be worth slightly more than $ 5. Expected to reach 7 billion U.S. dollars and 9. 48 billion marks in 2010. As the Indian pharmaceutical industry is growing and getting more and more players gear up to the global blockbuster on the Indian market, the competition is definitely going to heat up.

Many of these multinational companies are in collaboration with Indian companies, which often offer as much as 30% to 50% savings in total drug research and development costs. Recent amendments to patent laws of India and India have a more attractive drug discovery target. In 2005, India amended its patent laws in order to comply with the World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), an international treaty commission minimum standards for trade and the protection of intellectual property. These changes allowed for the first time in India of patent protection for pharmaceutical products. The previous law provided patent protection only for the process of production of the drug, not the drug itself Companies in India offer two types of opportunities for drug discovery and development: outsourcing and genuine cooperation.

The outsourcing model involves an alliance between one or more companies to discrete tasks or specific operations and processes previously done in-house. In this model, the company reserves soliciting research in general, the control of the technology and related assets, including intellectual property rights. More recently, a growing number of multinational companies in more collaborations with Indian pharmaceutical companies and contract research organizations have entered, far beyond task-driven outsourcing. These transactions are more complex intellectual property.

A poll recently by Price Waterhouse Coopers report says that India could be one of the top 10 global pharmaceutical markets by 2020. Thus, any pharmaceutical companies, research and development can be done in India is likely to patent its technology in India, and choose therefore need to be familiar with Indian patentability standards1. Indian pharmaceutical industry present scenario India currently provides nearly $ 6 billion of the $ 550 billion global pharmaceutical industry, but the trend is growing at 10 percent per year, compared with 7 percent annual growth for the world market as a whole.

Even during the Indian sector, only 8 percent of the worldwide industry as a whole is by volume and was thus fourth in the world makes this 13 per cent by value and its drug exports have grown 30 percent per year. Those Äúorganized, Au sector of the pharmaceutical industry in India consists of 250 and 300 businesses, representing 70 percent of the products on the market account, with the top 10 companies 30 percent. However, if the entire industry is estimated at nearly 20,000 companies, some of which are extremely low. About 75 percent of the demand for drugs in India is met by local production. According to the German Chemicals Association, in 2005, both in India Top 10 pharmaceutical company Ranbaxy, Cipla, Dr. Reddy’s Laboratories, lupine, Nicholas Piramal, Aurobindo Pharma, Cadila Pharmaceuticals, Sun Pharmaceuticals, Wockhardt Ltd. and Aventis Pharma. India’s potential attempt to further boost its already leading position in global generics production, as well as an offshore location for multinational drug companies to curb the rising cost of the manufacturing process, R & D and other support services stop provides an opportunity it is worth an estimated 48 billion U.S. dollars in 20082nd The pharmaceutical industry in India phenomenal advances made in the last 10 years. With over 8 billion U.S. dollars domestically and another $ 5 billion in exports in 2006, which has double-digit growth both recorded it to his place in the sun. She has also started its global presence and our more than $ 2 5 billion worth of acquisitions abroad were made in the past two years. Undoubtedly, the most important turning points in the history of the Indian pharmaceutical industry is the place of the product patent law in 2005.

This has doubled, leading many pharmaceutical majors almost their R & D investment, and it is probable that runs New Chemical Entities (NCE) from the Indian R & D labs start in a few years. But before we begin to pat ourselves on the back for these commendable achievements, we must not forget that India contributes less than two percent of global pharmaceutical sales of around 650 billion U.S. dollars. While McKinsey predicts a sale of $ 20 billion by the year 2015, we need to identify key strategic driver of growth and to use this leverage to accelerate the tempo. While stable economy, with eight to nine percent GDP growth will certainly be right environment for businesses, there are other internal factors that act as catalysts.

These are the intellectual property rights (IPR), government pricing policies, changes in legislation, scientific and technical personnel and capital funding3. The Indian pharmaceutical industry is currently the largest among developing countries and one of the flagship sectors of the Indian economy. Indian pharmaceutical companies continue to move to the center of the global pharmaceutical market. It is a worldwide trend of structural development in the fields of pharmaceuticals and Indian enterprises play a key role in this context, from his superior biotech and drug synthesis skills, high quality, vertically integrated manufacturing assets to distinguish business models and significant cost savings driven. The pharmaceutical industry in India has emerged as a renowned manufacturer of medical products that are currently meeting almost 95% of the domestic health care needs. From modest beginnings in 1970, today the total Indian pharmaceutical sector is valued at U.S. $ 8 8 billion with a growth rate of 8%.

The Indian pharmaceutical industry is a net exporter of bulk and generic products and is one of the 17th in the world in terms of bulk drugs and formulation exports. In 2004-05 was in the net pharmaceutical exports more than U.S. $ 3. 75 billion accounted for formulations to 55%, while the remaining 45% came from bulk drugs. U.S., Germany, Russia, Britain and China are the top five export markets for the Indian pharmaceutical industry sector4. Indian Pharmaceutical Industry: Scenario-2020 The pharmaceutical industry in India is expected to grow from $ 5. 5 billion now to $ 25 billion in 2010 and $ 75 billion U.S. dollars by 2020. By 2020, the global integration of most industries in the global economy would be much more pronounced, and the pharmaceutical industry is no exception. In fact, the Indian pharmaceutical industry, currently has close links with the global pharmaceutical market, are even more integrated. Overall, the pharmaceutical market is in transition is run by changing the demand structure, realignment of supply chains and global regulatory changes.

To predict the state of the Indian pharmaceutical market in 2020, it is useful to the current global environment of the pharmaceutical market and its main trends and analysis of the impact that these factors will have on the global as well as on the domestic pharma understand the market. Key trends in the global pharmaceutical industry have been declining R & D productivity, increasing use of generic drugs and the increase outsourcing5. India is expected that 30% of the contract in the world of research in the next 10-15 years, host, driven by the attractions of low costs and high quality standards, says the India Brand Equity Foundation IBEF. The IBEF cites a McKinsey forecast for the value of the pharmaceutical clinical trial outsourcing to India at $ 1 23 billion in 2010. This would be projected 7% of the total world market by Biopharm put at $ 18. 5 billion in 2010. India offers a huge cost advantage in clinical trials in comparison with Western countries.

A multinational company might move R & D in India to save 30-50%, says IBEF. Indian companies on the conduct of clinical trials, less than one tenth of U.S. costs. The U.S. National Institutes of Health study registry (www. clinical trials. Gov.) lists 272 trials actively recruiting patients in the country, of which 60% of Phase III. There currently are 70 CROs in India, according Biopharm, AOS Contract Research Annual Review 2006 – a figure that is projected to grow in the coming years. Several Western CROs have formed, including Aptuit (U.S.), Synergy Research Group (Russia) and ethica Clinical Research (Canada), alliances or joint ventures with their Indian counterparts in recent months.

Investment has also flowed in the opposite direction, with U.S. CROs Radiant Research and Taractec both groups of Indian purchase this year6. India is expected to be in the league of the top 10 pharmaceutical markets by 2020. According to the Government of India 06-07 in the annual report of the Indian pharmaceutical industry is worth about 12 billion U.S. dollars (more than 55,000 Rs crores) already includes the 4 U.S. dollars. 5 billion in the export of drugs, pharmaceuticals and fine chemicals. The pharmaceutical industry needs more R & D productivity and a better focus to exploit the enormous opportunities available. India, with its inherent competitive advantages and cost-effective production capacity, has now become one of the most popular destinations for Contract Research and Manufacturing Services (CramS). According to the KPMG report, India holds a huge potential for the $ 20 billion CramS businesses tap into the expected to reach 31 billion U.S. dollars by 2010. India, with its intrinsic competitive advantages remains as one of the most preferred outsourcing destinations and is now playing an important role in the production and drug development value chain of various companies7 innovator.

The Indian pharmaceutical industry is entering a period checked in the value chain components and revised in order to realize optimal value. While the cost increases of the companies that are customers are demanding more innovative pharmaceutical products at more competitive prices. The change in the patent regime has also announced a change in industry dynamics. Are on the one hand, patents on blockbuster drugs expire, and on the other hand, there are not enough drugs in the pipeline. The changing dynamics of the industry both nationally and internationally, has forced the pharmaceutical players to rethink their traditional business strategies. Conclusion The Indian market has some unique advantages. India has a 60-year-old vibrant democracy. It has an educated work force and English is the language of business.

It has a solid legal framework and strong financial markets. More than 9,000 companies are publicly listed. Professional services are easily accessible. There is already an established international industry and business. It has a good network of world-class educational institutions and established strengths in information technology. The country is now committed to an open economy and globalization. Above all, it has about 200 million middle class market that is growing steadily. Over time, the international pharmaceutical industry has been finding great opportunities in India. The Indian pharmaceutical players in the future continues to look forward with confidence. There are enormous opportunities for pharmaceutical players on both the domestic as well as at the global level, but chances are with challenges to be overcome, it is necessary to achieve sustainable growth in the future. The future will be very promising many more milestones in the journey of the Indian pharmaceutical industry.

References 1) http://www. dddmag. com / destination-India. aspx

2) http://www. KPMG. de/library/brochures_surveys/15646. asp

3) http://www. Nanowerk. com / news / newsid = 4226th php

To drive 4) Jayashri Kulkarni, sustainable growth strategies and leadership, pharmaceutical Bio World in January 2007, p. 72-80.

5) http://www. democraticunderground. com / discuss / duboard. php? view_all az = & address = 103×334073

6) http://www. prlog. org/10035055-india-to-host-30-of-global-clinical-research-by-2020. html

7) http://www. silobreaker. com / Document Reader. aspx? Item = 5_817288715

Share and Enjoy:
  • Digg
  • del.icio.us
  • Facebook
  • NewsVine
  • Reddit
  • StumbleUpon
  • Google Bookmarks
  • Yahoo! Buzz
  • Twitter
  • Technorati
  • Live
  • LinkedIn
  • MySpace
  • StumbleUpon
  • Technorati
  • Tipd

The biotechnology has made rapid developments in genetic engineering with a possibility of ‘tailoring’ organisms in order to optimize production of established or novel metabolites of commercial importance and of transferring genetic material (genes) from one organism to another. It has economized developing industrial processes with less energy and renewable raw materials thus it is an effective interdisciplinary and integrate natural and engineering sciences. Few textile industrial uses are focused here.

Fibers and Biopolymers: Cotton, wool and silk natural textile fibers are an asset but biotechnology producing unique fibers and improve yields of existing fibers. Cotton is leading worldwide textile fiber with ca 20 million tons grown/year by about 85 countries but it is vulnerable to many insects, and to maintain yields, large amounts of pesticides are in use. Cotton is prone to infestation by weeds under intense irrigation conditions and needs throughout its growth cycle, and has poor tolerance to any of the herbicides. Hence biotechnologists have put forward short-term objectives on genetically engineering insect, disease and herbicide resistance into cotton plant along with modification of fiber quality and properties to have high performance cottons. Naturally colored cottons are attracting the world market hence transgenic intensely colored cottons (blues and vivid reds) is dream of the day that can replace bleaching and dyeing.

Biotechnology has largely influenced animal fiber production, in vitro fertilization and embryo transfer, diagnostics, genetically engineered vaccines and therapeutic drugs are other catchments of it. CSIRO, Australia’s national research organization is put up efforts for genetic modification of sheep to resist attack from blowfly larvae by engineering a sheep that secretes an insect repellent from its hair follicles and ‘biological wool shearing’’. And is expected to artificial epidermal growth factor which on injection into sheep interrupts hair growth, within a month, it breaks up in wool fiber and fleece can be pulled off whole in half the time it takes to shear a sheep.

Fermentation is developing biopolymers at large-scale i.e. bacterial storage compound polyhydroxybutyrate (PHB) is developed by Zeneca Bioproducts and is as produced ‘Biopol’. It high molecular weight linear polyester and thermoplastic (melts at 180°C) and can be melt spun into biocompatible and biodegradable fibers suitable for surgical use where human body enzymes slowly degrade sutures. Biopol is being used as conventional plastics for shampoo bottles but it is not economic, research is on to produce Biopol from plants, probably from genetically engineered variety of rape. Polysaccharides chitin, alginate, dextran and hyaluronic acid biopolymers are of interest in wound healing as chitin and its derivative chitosan are important components of fungal cell walls, at present manufactured from sea food (shellfish) wastes. Patents taken out by Japanese Unitika cite a use of fibers made out of chitin in wound dressings. At BTTG, research has been directed for use of intact fungal filaments as a direct source of chitin or chitosan fiber to produce inexpensive wound dressings and other novel materials. Tests are carried out at Welsh School of Pharmacy indicate that these products have wound healing acceleration properties. Wound dressings based on calcium alginate fibers have already been developed by Courtaulds and are marketed as ‘Sorbsan’. Present supplies of this polysaccharide rely on its extraction from brown seaweed’s. However, a polymer of similar structure can also be produced by fermentation from certain species of bacteria. Dextran, which is manufactured by fermentation of sucrose by Leuconostoc mesenteroides or related species of bacteria, is also being developed as a fibrous non-woven for specialty end-uses such as wound dressings. Additional unique biopolymers are now coming onto market thanks to biotechnology e.g. hyaluronic acid a polydisaccharide of D-glucuronic acid and N-acetyl glucosamine found in connective tissue matrices of vertebrates and is also present in capsules of some bacteria. The original method of production by extraction from rooster combs was very inefficient requiring 5 kg of rooster combs to provide 4 g of hyaluronic acid. Fermentech, a British biotechnology company, is now producing hyaluronic acid by fermentation. The same amount of high quality purified hyaluronic acid can be obtained from 4 liters of fermentation broth as opposed to 5 kg of rooster combs.

Different biotechnological routes for cellulose production are being worked out globally, cellulose is produced as an extra cellular polysaccharide by several bacteria in form of ribbon-like micro fibrils, and can be used to produce moulded materials of relatively high strength. Sony, a Japanese electronics company has patented a way of making hi-fi loudspeaker cones and diaphragms from bacterial cellulose. An alternative route to cellulose, still at a very early stage of development, concerns in vitro cultivation of plant cells. Culturing cells of various strains of Gossypium can produce cotton fibers in vitro include a more uniform product displaying particularly desirable properties. Plant tissue culture can provide a steady, all year supply of products without climatic or geographic limitations free of contamination from pests. Proteins are interesting biopolymers for utilizing new genetic manipulation techniques where animal and plant proteins genes (e.g. collagen, various silks) can now be transferred into suitable microbial hosts and proteins produced by fermentation. US army is taking up spider silk as a high performance fiber for bulletproof vests.

Enzymes

Chemical reactions by catalytic proteins (enzymes) are a central feature of living systems, living cells makes enzymes although the enzymes themselves are not alive and we can encourage living cells to make more enzymes than they would normally make.  Or to make a slightly different enzyme (protein engineering) with improved characteristics of specificity, stability and performance in industrial processes and operate under mild conditions of pH and temperature. Many enzymes exhibit great specificity and stereo selectivity. With a notable exception of starch-size removal by amylases, however, scant attention is given to application of enzymes in textile processing for preparation textile fibers e.g. flax and hemp by dew retting involves action of pectolytic enzymes from various microorganisms, which degrade pectin in middle lamella of these plant fibers. Yet no attempts appear to be taken to use isolated enzyme preparations for desired effects although their effectiveness has been demonstrated in the laboratory.

Use of isolated enzymes to remove fats and waxes, pectin’s, seed-coat material and colored impurities from loom state cotton and cotton/polyester fabrics, leading to a novel, low-energy fabric-preparation process, (replace scouring and bleaching) is investigated at BTTG. Only partial success is made using existing commercial enzyme preparations due to the recalcitrant nature of some of components and process was found to be too slow and therefore uneconomic for current applications. Enzyme that is being applied in textile processing for removal of hydrogen peroxide prior to dyeing is catalase. Undoubtedly, use of microbial enzymes can be expected to expand into many other areas of textile industry replacing existing chemical or mechanical processes in not too distant future.

Contrary to textile processing enzymes are used in detergents since their inception in 1960’s, and washing powders are referred to as ‘biological’, and degrade stains with milder washing conditions at lower temperatures saving energy and protects fabric. Cellulose enzymes could replace pumice stones used to produce ’stone-washed’ denim garments, stones can damage clothes, particularly the hems and waistbands, and most manufacturers are now using enzyme treatment. Cellulose enzymes are in biopolishing, a removal of fuzz from surface of cellulosic fibers, which eliminates pilling making fabrics smoother and cleaner looking. Similarly protease enzymes are developed for wool.

Interesting uses of enzymes are in biotransformation with biocatalytic transformation of one chemical to another. In practice, either intact cells, an extract from such cells or an isolated enzyme may be used as the catalyst system of a specific reaction. Concentration of individual enzymes in cells is typically less than 1 per cent this can now be increased using gene amplification techniques. Bulk chemical production by oil-based processes is being replaced by biotransformations, biotechnology competes with chemical synthesis. For example, optical activity of chemicals as of polymer precursors is likely to grow and biotransformation has a particular edge over traditional chemical methods.

Textile Auxiliaries: These are dyes produced by fermentation or from plants in future in the nineteenth century many of colors used to dye textiles came from plants e.g. woad, indigo and madder. Many microorganisms produce pigments during their growth, which are substantive as indicated by permanent staining and associated with mildew growth on textiles and plastics. Some species produce up to 30% of their dry weight as pigment, such microbial pigments are benzoquinone, naphthoquinone, anthraquinone, and perinaphthenone and benzofluoranthenequinone derivatives, resembling in some instances the important group of vat dyes. Microorganisms offer great potential for direct production of novel textile dyes or dye intermediates by controlled fermentation techniques replacing chemical synthesis. Production and evaluation of microbial pigments as textile colorants is currently being investigated at BTTG. Another biotechnological route for producing pigments for use in food, cosmetics or textile industries is from plant cell culture, e.g. red pigment shikonin (cosmetics) is being commercially produced since 1983 in Japan. Shikonin was extracted from roots of five-year-old Lithosperum erythrorhiz plants where it makes up about 1 to 2 percent of dry weight of roots. In tissue culture, pigment yields of about 15 percent of dry weight of root cells have been achieved.

New Analytical Tools: Work on molecular biology at BTTG has led to development of species-specific DNA probes for animal fibers to detect adulteration of high value specialty fibers such as cashmere by much cheaper fibers e.g. wool and yak hair. Rapid methods are being evolved to assist in early detection of biodeterioration of textile and other materials. BTTG have shown that presence of viable microorganisms on textiles can be assessed using enzyme luciferase isolated from firefly (Photinus pyralis), which releases light (bioluminescence) in combination with ATP produced by the microorganisms.

Waste Management: Microbes or their enzymes are being used to degrade toxic wastes instead of traditional processes, thus waste treatment is useful industrial asset of biotechnology. In textile industry color removal from dyehouse effluent, toxic heavy metal compounds and pentachlorophenol used overseas as a rot-proofing treatment of cotton fabrics but washed out during subsequent processing in the UK pose a challenge for disposal. Currently efforts are on to resolve such problems perhaps biotechnology would appear to offer the most effective solutions.

Conclusions: Biotechnology is being treated as upcoming science with enormous commercial implications for many industrial sectors in years to come. It has successfully developed new products, opened up new doors, expedited production and helped to clean up environment. Mainly biotechnology is contributing a lot to textile industries but it current awareness is low. Michael Heseltine recently launched ‘Biotechnology Means Business’ initiative in the UK to inform companies about biotechnology and put them in touch with experts to deploy biotechnology to give a competitive edge to their business to win new markets. E.g. downstream processing after fermentation accounts for at least 70 percent of production costs in biotechnology and there is the need for improved filtration and separation techniques. Hollow fibers and membranes, which separate molecules according to size, are finding increased application in this area.

Enzymes are used in detergents e.g. protease removes stains caused by proteins such as blood, grass, egg and human sweat. Amylase removes starch-based stains such as those made by potatoes, pasta, rice and custard. Lipase breaks down fats, oils and greases removing stains based on salad oils, butter, fat-based sauces and soups, and certain cosmetics such as lipstick. Cellulase brightens and softens the fabric, and release particles of dirt trapped in the fibers. Briefly biotechnology improves plant varieties used in production of textile fibers and in fiber properties, and derives fibers from animals and health care of the animals along with novel fibers from biopolymers and genetically modified microorganisms. The survismeter is a effective tool to characterize broth fermentation.

References

Glossary: Biotechnology: Use of living organisms or their cellular, sub cellular or molecular constituents to manufacture products and establish processes. DNA: Deoxyribonucleic acid, chemical molecule to carry hereditary information to pass from parent to offspring. DNA Probe: Single DNA strand used to detect a presence of complementary strands of DNA. Enzymes: Protein molecules that speed up specific chemical reactions and remain unchanged. Gene: Unit of heredity composed of DNA.

Genetic Engineering: A range of techniques for manipulating DNA and thereby modifying the genetic structure of living organisms. Transgenesis: Stable incorporation of foreign DNA from one species into another. For example, incorporating genes from a bacterium has developed insect resistant transgenic plants.

 

Share and Enjoy:
  • Digg
  • del.icio.us
  • Facebook
  • NewsVine
  • Reddit
  • StumbleUpon
  • Google Bookmarks
  • Yahoo! Buzz
  • Twitter
  • Technorati
  • Live
  • LinkedIn
  • MySpace
  • StumbleUpon
  • Technorati
  • Tipd